Drugs / CT-SP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07028008 | Oct 2025 → May 2027 expected | melanoma | Samsung Medical Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-SP | “tumor-infiltrating lymphocyte (TIL): CT-SP 1\~100 x10 9 cells” NCT07028008 ↗ |
| Modality | Cell therapy | “tumor-infiltrating lymphocyte (TIL) therapy” NCT07028008 ↗ |
| Route | Intravenous | “1time, IV” NCT07028008 ↗ |